Sclerostin monoclonal antibody enhanced bone fracture healing in an open osteotomy model in rats

Journal of Orthopaedic Research

Volumn 32, Issue 8, 2014, Pages 997-1005

  Suen, Pui Kit ^a   He, Yi Xin ^a   Chow, Dick Ho Kiu ^a   Huang, Le ^a   Li, Chaoyang ^b   Ke, Hua Zhu ^b   Ominsky, Michael S ^b   Qin, Ling ^a,c  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b AMGEN INC   (United States)

^c SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY   (China)

Author keywords

fracture healing; osteotomy; sclerostin; sclerostin monoclonal antibody

Indexed keywords

MONOCLONAL ANTIBODY; SCLEROSTIN; SCLEROSTIN MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MASS; BONE RADIOGRAPHY; BONE STRENGTH; CALLUS; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DISEASE COURSE; FEMUR OSTEOTOMY; FLUORESCENCE MICROSCOPY; FRACTURE HEALING; MALE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; TREATMENT DURATION;

FRACTURE HEALING; OSTEOTOMY; SCLEROSTIN; SCLEROSTIN MONOCLONAL ANTIBODY;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE MORPHOGENETIC PROTEINS; BONY CALLUS; FEMORAL FRACTURES; FEMUR; FRACTURE HEALING; GENETIC MARKERS; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; OSTEOTOMY; RATS; X-RAY MICROTOMOGRAPHY;

EID: 84903303547     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.22636     Document Type: Article

References (40)

1. Agholme F, Aspenberg P., 2011. Wnt signaling and orthopedics, an overview. Acta Orthop 82: 125-130.
2. Balemans W, Ebeling M, Patel N, et al. 2001. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10: 537-543.
3. Li X, Ominsky MS, Niu QT, et al. 2008. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23: 860-869.
4. Kramer I, Loots GG, Studer A, et al. 2010. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 25: 178-189.
5. Li X, Ominsky MS, Warmington KS, et al. 2009. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24: 578-588.
6. Ke HZ, Richards WG, Li X, et al. 2012. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 33: 747-783.
7. Ellman R, Ferguson VL, Livingston EW, et al. 2012. Site- and compartment-specific effects of microgravity on the skeleton in mice flown on the STS-135 shuttle mission. J Bone Miner Res 27 (Suppl 1). Available at http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid= 5aca4f21-dae4-4a92-add4-196287ecbe79. Accessed February 01, 2013.
8. Padhi D, Jang G, Stouch B, et al. 2011. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26: 19-26.
9. McDonald MM, Morse A, Mikulec K, et al. 2012. Inhibition of sclerostin by systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectomized rats. J Orthop Res 30: 1541-1548.
10. Jawad MU, Fritton KE, Ma T, et al. 2013. Effects of sclerostin antibody on healing of a non-critical size femoral bone defect. J Orthop Res 31: 155-163.
11. Virk MS, Alaee F, Tang H, et al. 2013. Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model. J Bone Joint Surg Am 95: 694-701.
12. Hamann C, Rauner M, Hohna Y, et al. 2013. Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J Bone Miner Res 28: 627-638.
13. Park SH, O'Connor K, Sung R, et al. 1999. Comparison of healing process in open osteotomy model and closed fracture model. J Orthop Trauma 13: 114-120.
14. Gaebler C, Berger U, Schandelmaier P, et al. 2001. Rates and odds ratios for complications in closed and open tibial fractures treated with unreamed, small diameter tibial nails: a multicenter analysis of 467 cases. J Orthop Trauma 15: 415-423.
15. Hao YJ, Zhang G, Wang YS, et al. 2007. Changes of microstructure and mineralized tissue in the middle and late phase of osteoporotic fracture healing in rats. Bone 41: 631-638.
16. Tagil M, McDonald MM, Morse A, et al. 2010. Intermittent PTH(1-34) does not increase union rates in open rat femoral fractures and exhibits attenuated anabolic effects compared to closed fractures. Bone 46: 852-859.
17. Kratzel C, Bergmann C, Duda G, et al. 2008. Characterization of a rat osteotomy model with impaired healing. BMC Musculoskelet Disord 9: 135.
18. Ominsky MS, Li C, Li X, et al. 2011. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res 26: 1012-1021.
19. Chow DH, Suen PK, Fu LH, et al. 2012. Extracorporeal shockwave therapy for treatment of delayed tendon-bone insertion healing in a rabbit model: a dose-response study. Am J Sports Med 40: 2862-2871.
20. He YX, Liu Z, Pan XH, et al. 2012. Deletion of estrogen receptor beta accelerates early stage of bone healing in a mouse osteotomy model. Osteoporos Int 23: 377-389.
21. Siu WS, Qin L, Leung KS., 2003. pQCT bone strength index may serve as a better predictor than bone mineral density for long bone breaking strength. J Bone Miner Res 21: 316-322.
22. Shi HF, Cheung WH, Qin L, et al. 2010. Low-magnitude high-frequency vibration treatment augments fracture healing in ovariectomy-induced osteoporotic bone. Bone 46: 1299-1305.
23. Fang TD, Salim A, Xia W, et al. 2005. Angiogenesis is required for successful bone induction during distraction osteogenesis. J Bone Miner Res 20: 1114-1124.
24. Jacobsen KA, Al-Aql ZS, Wan C, et al. 2008. Bone formation during distraction osteogenesis is dependent on both VEGFR1 and VEGFR2 signaling. J Bone Miner Res 23: 596-609.
25. Wang Y, Wan C, Deng L, et al. 2007. The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest 117: 1616-1626.
26. Chen D, Tian W, Li Y, et al. 2012. Osteoblast-specific transcription factor Osterix (Osx) and HIF-1alpha cooperatively regulate gene expression of vascular endothelial growth factor (VEGF). Biochem Biophys Res Commun 424: 176-181.
27. Tang WJ, Yang F, Li Y, et al. 2012. Transcriptional regulation of vascular endothelial growth factor (VEGF) by osteoblast-specific transcription factor osterix (Osx) in osteoblasts. J Biol Chem 287: 1671-1678.
28. Zerlin M, Julius MA, Kitajewski J., 2008. Wnt/Frizzled signaling in angiogenesis. Angiogenesis 11: 63-69.
29. Easwaran V, Lee SH, Inge L, et al. 2003. beta-Catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Res 63: 3145-3153.
30. Maes C, Goossens S, Bartunkova S, et al. 2010. Increased skeletal VEGF enhances beta-catenin activity and results in excessively ossified bones. EMBO J 29: 424-441.
31. Chen D, Li Y, Zhou Z, et al. 2013. HIF-1alpha inhibits Wnt signaling pathway by activating Sost expression in osteoblasts. PLoS ONE 8: e65940.
32. Zhang C, Cho K, Huang Y, et al. 2008. Inhibition of Wnt signaling by the osteoblast-specific transcription factor Osterix. Proc Natl Acad Sci USA 105: 6936-6941.
33. Chen D, Li Y, Zhou Z, et al. 2012. Synergistic inhibition of Wnt pathway by HIF-1alpha and osteoblast-specific transcription factor osterix (Osx) in osteoblasts. PLoS ONE 7: e52948.
34. Hankenson KD, Dishowitz M, Gray C, et al. 2011. Angiogenesis in bone regeneration. Injury 42: 556-561.
35. Marsell R, Einhorn TA., 2011. The biology of fracture healing. Injury 42: 551-555.
36. Okike K, Bhattacharyya T., 2006. Trends in the management of open fractures. A critical analysis. J Bone Joint Surg Am 88: 2739-2748.
37. Mathavan N, Bosemark P, Isaksson H, et al. 2013. Investigating the synergistic efficacy of BMP-7 and zoledronate on bone allografts using an open rat osteotomy model. Bone 56: 440-448.
38. Bosemark P, Isaksson H, McDonald MM, et al. 2013. Augmentation of autologous bone graft by a combination of bone morphogenic protein and bisphosphonate increased both callus volume and strength. Acta Orthop 84: 106-111.
39. Colnot C., 2009. Skeletal cell fate decisions within periosteum and bone marrow during bone regeneration. J Bone Miner Res 24: 274-282.
40. Utvag SE, Grundnes O, Reikeraos O., 1996. Effects of periosteal stripping on healing of segmental fractures in rats. J Orthop Trauma 10: 279-284.